

Seikagaku Corporation

[View the current Seikagaku Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/29815-Seikagaku+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/29815-Seikagaku+Corporation.html>)

Contact Details:

Tel:

Fax:

Email:

Nil

Recent Publications by Seikagaku Corporation:



- [Generation and characterization of a series of monoclonal antibodies that specifically recognize \[HexA\(+/-2S\)-GlcNAc\]_n epitopes in heparan sulfate.](#)
*Five monoclonal antibodies AS17, 22, 25, 38 and 48, a single monoclonal...*5th February, 2009
Central Research Laboratories, Seikagaku Corporation, 3-1253 Tateno,- Glycoconj J. 2008 Nov;25(8):703-12. Epub 2008 May 7. ([DOI Direct Link](#))
- [Tetrasulfated disaccharide unit in heparan sulfate: enzymatic formation and tissue distribution.](#)
*We previously reported that the heparan sulfate 3-O-sulfotransferase...*24th December, 2008
Central Research Laboratories, Seikagaku Corporation, 3-1253 Tateno,- J Biol Chem. 2008 Nov 7;283(45):31237-45. Epub 2008 Aug 28. ([DOI Direct Link](#))
- [Analytical method to determine keratan sulfate in the serum using HPLC.](#)
*There is an established method to assess the extent of articular cartilage...*30th July, 2008
Seikagaku Corporation, Yokosuka.- Rinsho Byori. 2008 May;56(5):373-8.
- [Identification of N-glycan-binding proteins for E3 ubiquitin ligases.](#)
*N-glycans serve as a degradation signal by the SCF(Fbx2) ubiquitin ligase...*6th February, 2007
Seikagaku Corporation, Central Research Laboratories, Tokyo, Japan.- Methods Enzymol. 2006;415:20-30. ([DOI Direct Link](#))
- [Application of fluorophore-assisted carbohydrate electrophoresis to analysis of disaccharides and oligosaccharides derived from glycosaminoglycans.](#)
*Various combinations of fluorescent dyes, polyacrylamide gels, and...*8th November, 2005
Seikagaku Corporation, Central Research Laboratories, 1253, Tateno- Anal Biochem. 2005 Aug 15;343(2):212-22. ([DOI Direct Link](#))
- [The keratan sulfate disaccharide Gal\(6S03\) beta1,4-GlcNAc\(6S03\) modulates interleukin 12 production by macrophages in murine Thy-1 type autoimmune disease.](#)

*It has been reported that disaccharides of the glycosaminoglycans (GAGs),...*16th August, 2005
Seikagaku Corporation, 1-5, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo- J Biol Chem. 2005 May
27;280(21):20879-86. Epub 2005 Mar 4. ([DOI Direct Link](#))

- [Synthetic examination of incorrectly proposed structures of biomolecules.](#)
*Many incorrect structures of biomolecules have been proposed for natural...*17th June, 2005
Glycosphingolipid Synthesis Group, Laboratory for Immune Regulation, RIKEN- Chem Rec.
2005;5(1):1-16. ([DOI Direct Link](#))
- [Limitation of polymyxin B on suppression of endotoxin shock induced by Salmonella infection in mice.](#)
*The protective effects of an antibiotic polymyxin B (PLB), having...*20th April, 2005
Seikagaku Corporation, Tokyo, Japan.- Biol Pharm Bull. 2004 Nov;27(11):1840-3.
- [Evaluation of in vivo biocompatibility and biodegradation of photocrosslinked hyaluronate hydrogels \(HADgels\).](#)
*HADgels are newly developed photocrosslinked hyaluronate hydrogels. They...*23rd March, 2005
Medical Device Research Group, Central Research Laboratories, Seikagaku- J Biomed Mater Res A.
2004 Sep 15;70(4):550-9. ([DOI Direct Link](#))
- [\[Treatment of lumbar intervertebral disc displacement with chondroitinase ABC--experimental basis for clinical application\]](#)
*After single intradiscal injection of C-ABC in rabbit inter-vertebral...*8th February, 2005
Central Research Laboratories, Seikagaku Corporation.- Clin Calcium. 2004 Jul;14(7):85-9. ([DOI Direct Link](#))
- [Isolation and partial characterization of fucan sulfates from the body wall of sea cucumber Stichopus japonicus and their ability to inhibit osteoclastogenesis.](#)
*Two types of fucan sulfate were isolated from chloroform/methanol extract...*24th December, 2004
Central Research Laboratories, Seikagaku Corporation, 3-1253 Tateno,- Carbohydr Res. 2004 May
17;339(7):1339-46. ([DOI Direct Link](#))
- [Immunogenicity of hylan g-f 20 in Guinea pigs and mice.](#)
*OBJECTIVE: To determine the product-specific immunogenicity of a...*10th August, 2004
Central Research Laboratories, Seikagaku Corporation, Tokyo, Japan.- J Rheumatol. 2004
May;31(5):943-50.
- [The role of sulfatide in thrombogenesis and haemostasis.](#)
*In 1961, Wago et al. reported a potential anticoagulant role for sulfatide...*20th July, 2004
Seikagaku Corporation, Central Research Laboratories, 1253 Tateno 3 chome,- Arch Biochem
Biophys. 2004 Jun 15;426(2):157-62. ([DOI Direct Link](#))
- [Enhancement of neurite outgrowth-promoting activity by heparin derivatives in sodium chlorate-treated explant cultures of rat central neurons.](#)
*Periodate-oxidized/borohydride-reduced 2-O-desulfated heparin (OR2DSH) was...*14th April, 2004
Central Research Laboratories, Seikagaku Corporation, 3-1253 Tateno,- J Biochem. 2003
Jun;133(6):783-90.
- [Contradictory functions of the sulfatide in the blood coagulation system.](#)
*It has long been controversial whether sulfatide stimulates blood...*3rd December, 2003
Seikagaku Corporation Tokyo Research Institute, 1253, Tateno 3-chome- Adv Exp Med Biol.
2001;491:343-50.

Press Releases on Seikagaku Corporation:

[FDA Accepts Once](#)

[Daily 23 mg Aricept\(R\)](#) 24th November,

[Extended Release](#) 2009

[NDA for Review](#)

Eisai Inc.

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ --
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug

[BMP Sunstone to Present at Piper Jaffray Health Care Conference](#)

24th November, 2009

BMP Sunstone Corporation

PLYMOUTH MEETING, Pa., Nov. 24 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that the Company will

[BioMarin to Present at the NASDAQ OMX 23rd Investor Program](#)

24th November, 2009

BioMarin Pharmaceutical Inc.

NOVATO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company

[Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi](#)

24th November, 2009

Centene Corporation

ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that the Mississippi Division of Medicaid has selected Centene as one of two Coordinated Care Organizations

[Sigma-Aldrich to Present at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009](#)

24th November, 2009

Sigma-Aldrich Corporation

ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) will be presenting at the NASDAQ OMX conference on Tuesday, December 1st at 1:45 PM GMT in London, 7:45 AM US/CST.

BioNews Results for Seikagaku Corporation



- [Agent for treating inflammatory bowel diseases](#)
PharmCast: Oct 13 2009 4:09AM Matching: seikagaku

Seikagaku Corporation Patents:



- 6228998- [Amino spacers glycosaminoglycan derivatives and their use in copolymerization with acrylamide](#)

- 6492503- [Glycosaminoglycan and drug compositions containing the same](#)
- 6498246- [Glycosaminoglycan derivatives and processes for preparing same](#)
- 6537977- [Anti-inflammatory agent](#)
- 6545136- [Process for producing desulfated polysaccharide, and desulfated heparin](#)
- 6548487- [Agent for treatment of bladder troubles](#)
- 6555371- [Sialyltransferase and DNA encoding the same](#)
- 6562954- [Method for producing oligosaccharide, and novel oligosaccharide and pharmaceutical composition containing the same](#)
- 6602859- [Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked-hyaluronic acid derivative and medical material using the same](#)
- 6783966- [Alpha1, 4-galactosyltransferase and DNA encoding thereof](#)
- 6809086- [Process for producing desulfated polysaccharide, and desulfated heparin](#)
- 6455289- [Polypeptide of N-acetylglucosamine-6-O-sulfotransferase and DNA encoding the same](#)
- 6436911- [IL-12 production inhibitor](#)
- 6407064- [Aminoalcohol derivative and medicament comprising the same](#)
- 6232301- [Remedies for bladder disorders](#)
- 6245897- [Monoclonal antibody recognizing cell surface antigen CD14](#)
- 6284885- [Process for preparing \(1.fwdarw.3\)-.beta.-D-glucan from fungi](#)
- 6288113- [Angiogenesis promoters](#)
- 6306577- [Method for measuring enzyme reaction](#)
- 6329498- [Polypeptide transition metal salts and method of enhancing anti-HIV activity of polypeptide](#)
- 6335444- [Amino alcohol derivative and method for preparing the same](#)
- 6365733- [Lactosamine oligosaccharide and method for producing the same](#)
- 6372466- [C-4 specific sulfotransferase](#)
- 6376203- [Glycoglycerophospholipid, antibody thereagainst, and method for detecting mycoplasma](#)
- 6903223- [Phenyldiazirine compounds and photoaffinity labeling reagent](#)
- 7008626- [Medical composition for protuberance of epithelium](#)
- 7396818- [Sulfotransferase inhibitor](#)
- 7452856- [Antibacterial peptide](#)
- 7468265- [Stabilizing agent for enzymes](#)
- 7470529- [Chondroitin synthase and nucleic acid encoding the enzyme](#)
- 7476730- [Sulfotransferase and DNA encoding the enzyme](#)
- 7485755- [Acid addition salt of carbasugar amine derivative](#)
- 7507723- [Hyaluronic acid oligosaccharide fractions and drugs containing the same](#)
- 7511026- [Therapeutic agent for nerve damage](#)
- 7541162- [Method for producing factor G derived from horseshoe crab](#)
- 7598068- [Chondroitin polymerase and DNA encoding the same](#)
- 7393672- [DNA coding for endo-.beta.-galactosidase](#)
- 7365153- [Biologically active peptide and agent containing the same](#)
- 7365059- [Photocrosslinked-polysaccharide composition and production process of the same](#)
- 7052882- [Glucan derived from aspergillus](#)
- 7060483- [DNA encoding endo-.beta.-galactosidase](#)
- 7150981- [Sulfate transferase and DNA encoding this enzyme](#)
- 7232676- [Chondroitin synthase and nucleic acid encoding the enzyme](#)
- 7256278- [Sialyltransferase and DNA encoding the same](#)
- 7273729- [Chondroitin synthase and DNA encoding the enzyme](#)
- 7326799- [Epoxy-carboxamide compound, azide compound, and amino alcohol compound, and process for preparing alpha-keto amide compound using them](#)
- 7333847- [Method for evaluation of tissue adhesion level](#)
- 7335515- [\(1.fwdarw.3\)-.beta.-D-glucan binding domain protein, measuring method using the substance and assay kit](#)
- 7354910- [Agent for treating inflammatory bowel diseases](#)
- 7601488- [Hyaluronic acid oligosaccharide fractions and drugs containing the same](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

